Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.

Ruiyun Zhang Jingyu Zang Di Jin Feng Xie Akezhouli Shahatiaili Guangyu Wu Lu Zhang Lu Wang Yue Zhang Zhixin Zhao Pan Du Shidong Jia Jinhai Fan Guanglei Zhuang Haige Chen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

These findings demonstrate the safety and efficacy of neoadjuvant toripalimab, and suggest the immense potential of noninvasive utDNA MRD testing to guide tailored decision-making with regard to bladder preservation and change the current treatment paradigm for MIBC patients.

Keyphrases

rectal cancer
muscle invasive bladder cancer
end stage renal disease
decision making
lymph node
locally advanced
ejection fraction
chronic kidney disease
prognostic factors
spinal cord injury
peritoneal dialysis
single molecule
smoking cessation